Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Berzosertib · 1 trial · 1 indication
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment-related AEs: reasonably related to the study intervention.
| Arm | Type | Description |
|---|---|---|
| Part A1: Berzosertib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Berzosertib | DRUG | Participants received intravenous infusion of Berzosertib at a dose of 126 milligrams (mg) on Days 1, 8 and 15 until disease progression or unacceptable toxicity occurred. |
Inclusion Criteria: * Participants ongoing treatment in Vertex study VX13-970-002. * Participant must be able to understand and provide written informed consent. * Participant must be willing and able to comply with the scheduled visits, treatment plan, lifestyle, laboratory tests, contraceptive gu...
Berzosertib is an investigational small molecule being studied for the treatment of advanced stage solid tumors. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
Berzosertib is being developed by Merck KGaA, a company traded under the ticker MKGAF. The drug is currently in Phase 1 clinical trials for advanced stage solid tumors.
Berzosertib is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.
Berzosertib has one completed Phase 1 trial, identified as NCT03309150, titled 'ATRi Transition Rollover Study'. This trial enrolled one participant with advanced stage solid tumors in the United Kingdom.
Berzosertib is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for advanced stage solid tumors, and its safety and efficacy have not been established.